These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31647157)

  • 41. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
    Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
    PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ixabepilone.
    Stein A
    Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic polymorphisms of lysophosphatidic acid receptor 1 are associated with the onset of taxane-induced peripheral neuropathy.
    Tsuchida R; Tanabe Y; Nishizawa D; Ikeda K; Abe H; Inoue R; Kurano M; Yatomi Y; Tamura K; Takano T; Shimizu C; Uchida K; Sumitani M
    Br J Anaesth; 2021 Aug; 127(2):e43-e46. PubMed ID: 34024637
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
    Engvall K; Gréen H; Fredrikson M; Lagerlund M; Lewin F; Åvall-Lundqvist E
    Breast Cancer Res Treat; 2022 Oct; 195(3):379-391. PubMed ID: 35941422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
    Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
    Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
    Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy.
    Derman BA; Davis AM
    JAMA; 2021 Sep; 326(11):1058-1059. PubMed ID: 34546311
    [No Abstract]   [Full Text] [Related]  

  • 49. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy-induced peripheral neurotoxicity: Facts, needs and future directions.
    Cavaletti G; Cornblath DR
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S86-S87. PubMed ID: 31647156
    [No Abstract]   [Full Text] [Related]  

  • 51. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
    Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
    Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    McEvoy L; Cliff J; Carr DF; Jorgensen A; Lord R; Pirmohamed M
    Front Pharmacol; 2023; 14():1178421. PubMed ID: 37469869
    [No Abstract]   [Full Text] [Related]  

  • 54. Techniques for the neurological examination of taxane-induced neuropathy.
    Ohsumi S; Sunada Y
    Breast Cancer; 2004; 11(1):86-91. PubMed ID: 14718799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
    Farshchian N; Alavi A; Heydarheydari S; Moradian N
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
    Osmani K; Vignes S; Aissi M; Wade F; Milani P; Lévy BI; Kubis N
    J Neurol; 2012 Sep; 259(9):1936-43. PubMed ID: 22349867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical features of taxane neuropathy.
    Kudlowitz D; Muggia F
    Anticancer Drugs; 2014 May; 25(5):495-501. PubMed ID: 24300917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
    Battaglini E; Park SB; Barnes EH; Goldstein D
    Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing taxane toxicities.
    Markman M
    Support Care Cancer; 2003 Mar; 11(3):144-7. PubMed ID: 12618923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer.
    Maxwell C
    Clin J Oncol Nurs; 2013 Feb; 17 Suppl():35-40. PubMed ID: 23360701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.